Taft’s Intellectual Property Litigation practice and two partners are included in the sixth edition of "IAM Patent 1000 – The World’s Leading Patent Professionals," published by Intellectual Asset Management (IAM) magazine. In the guide, Taft received Bronze band honors for “the firm’s combination of cutting-edge Hatch-Waxman and Biologics Price Competition and Innovation Act competency with reasonable rates.” Partners Stephen Auten and Richard Ruzich were recognized as Leading Patent Practitioners. IAM notes that “[g]eneric drug companies … make beelines to Auten and Ruzich when they need to get results.”
The guide conducts intensive research and interviews to identify the top patent professionals and practices. Individuals qualify for the IAM Patent 1000 once they receive sufficient positive feedback from peers and clients with knowledge of their practice and the market within which they operate. Only those individuals identified by market sources for their exceptional skill sets and profound insights into patent matters are featured in the guide.
Auten is head of Taft's Pharmaceutical and Life Sciences Litigation practice. He is a widely recognized and seasoned attorney in Hatch-Waxman and biosimilar matters, including related patent litigation, and is followed by key industry leaders (brand and generic alike), law firms, analysts, educators and others on his LinkedIn blog "Hatch Waxman ANDA Litigation Forum," which has more than 8,000 members worldwide. He currently represents clients primarily in the areas of Paragraph IV design strategies, Hatch-Waxman litigation and biosimilar market opportunities.
Ruzich is an internationally recognized patent attorney who focuses on complex patent litigation, representing generic pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigation under the Hatch-Waxman statutory framework. An accomplished trial and appellate advocate, registered patent attorney and frequent lecturer and author, he is known worldwide for his legal work on behalf of his generic clients, including biosimilar sponsors. His experience covers the entire lifecycle spectrum from product selection, Paragraph IV development and through to market entry, including at-risk launches.